🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

114 results for “CG” Clear

  1. GIA632, Placebo to GIA632 150 mg/mL solution for injection

    Novartis Ophthalmics Europe

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  2. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Pharma Mar S.A.

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  3. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Ophthalmics Europe

    Schizophrenia

    phase 2 small molecule active

    1 trial

  4. Gecacitinib

    China SXT Pharmaceuticals

    cGVHD

    phase 2 small molecule active

    1 trial

  5. GnRHa/ hCG/ hMG

    China SXT Pharmaceuticals

    Azoospermia

    phase 2 small molecule active

    1 trial

  6. Green Tea Polyphenols (EGCG/ECG)

    China SXT Pharmaceuticals

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  7. IBRANCE 75 mg hard capsules, EXEMESTANE, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, TAMOXIFEN, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, IBRANCE 125 mg hard capsules, ANASTROZOLE, IBRANCE 75 mg hard capsules, CYCLOPHOSPHAMIDE, DOCETAXEL, IBRANCE 100 mg hard capsules, IBRANCE 100 mg film-coated tablets, IBRANCE 100 mg hard capsul

    Cancer Prevention Pharma (Ireland) Limited

    Localized ER+ breast cancer

    phase 2 small molecule active

    1 trial

  8. IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  9. IPILIMUMAB, NIVOLUMAB

    Cancer Prevention Pharma (Ireland) Limited

    type B3 thymoma and thymic carcinoma

    phase 2 small molecule active

    1 trial

  10. ISIS-GCGRRx

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  11. ISIS-GCGRRx - Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  12. ISIS-GCGRRx- Dose Level 1

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  13. Ibrutinib, IMBRUVICA 140 mg film-coated tablets, Ibrutinib, Prednison acis 5 mg, Tabletten, Prednison acis 20 mg, Tabletten, Ibrutinib, Prednison acis 50 mg, Tabletten

    AbbVie Deutschland GmbH & Co. KG

    Chronic Graft Versus Host Disease (cGVHD)

    phase 2 small molecule active

    1 trial

  14. Ivaltinostat

    CG Oncology

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  16. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  17. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Ophthalmics Europe

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  18. OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., N-803 (NAI), OncoTICE® 2-8 x 108 vermehrungsfähige Einheiten Pulver zur Herstellung einer Suspension zur intravesikalen Instillation

    Immunitybio Ireland Limited

    Non-Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  19. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Cancer Prevention Pharma (Ireland) Limited

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  20. RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

    United Therapeutics Europe Ltd

    Plasmodium Falciparum Malaria

    phase 2 mab completed

    1 trial

  21. Sodio cloruro S.A.L.F. 0,9% solvente per uso parenterale., BCG 10 Anti-Tuberculosis Vaccine, Powder and solvent for suspension for intradermal injection Vaccinum tuberculosis (BCG) cryodesiccatum

    Fondazione Telethon ETS

    RIS (Radiologically Isolated Syndrome)

    phase 2 small molecule active

    1 trial

  22. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Cancer Prevention Pharma (Ireland) Limited

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial

  23. TRASTUZUMAB, FULVESTRANT, EXEMESTANE, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, PERTUZUMAB, TUKYSA 150 mg film-coated tablets, LETROZOLE, TUKYSA 50 mg film-coated tablets, TRASTUZUMAB, ANASTROZOLE

    Cancer Prevention Pharma (Ireland) Limited

    HER2+ metastatic breast cancer with isolated brain progression

    phase 2 small molecule active

    1 trial

  24. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Cancer Prevention Pharma (Ireland) Limited

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources